Name
Madrigal Pharmaceuticals
Company Description
Madrigal Pharmaceuticals is focused on developing novel small-molecule drugs for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (nonalcoholic fatty liver disease, or NASH). Its lead candidate is MGL-3196, an oral drug for the treatment of NASH and hypercholesterolemia. Looking to enter new areas of development, Synta Pharmaceuticals merged with private firm Madrigal in 2016 and took the latter's name. Prior to the merger, Synta's preclinical research efforts
Website
Phone
215-239-3795
Address
500 Office Center Drive; Suite 400
Fort Washington, PA 19034
United States
Fort Washington, PA 19034
United States